Study of Enzyme Supplements to Treat Celiac Disease

Status Completed

Clinical Trial Summary

The purpose of this study is to examine whether a cocktail of two common food-grade enzyme supplements leads to decrease of serum activity markers in celiac disease patients insufficiently treated by previous gluten exclusion.

Clinical Trial Description

Celiac disease is genetically determined abnormal immune response to gluten, a component of wheat, rye and barley proteins that cause damage to the villous structure in the small bowel. The active disease is characterized by the induction of gluten-dependent autoantibodies to transglutaminase type-2, which are sensitive and specific non-invasive markers of gluten-sensitivity. Gluten-free diet normally leads to clearance of antibodies from serum in 6-12 months. Persistent seropositivity is a problem in patients who only incompletely exclude gluten or frequently transgress the diet. In such cases, damage of the small bowel may persist and complications may occur at higher frequency. The central hypothesis to be tested is that enzyme treatment designed to degrade a certain amount of gluten before absorption in the gastrointestinal tract will lead to a clinically meaningful decrease in auto-antibody levels in these patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00962182
Study type	Interventional
Source	Heim Pal Children's Hospital
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	August 2008
Completion date	December 2017

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04349904` - Near-Focus NBI Classification of Villous Atrophy in Suspected Coeliac Disease: International Development and Validation
Recruiting	`NCT05581628` - FREQUENCY OF FIBROMYALGIA IN PATIENTS WITH CELIAC DISEASE
Completed	`NCT04593251` - Dose Escalation Study to Evaluate an Experimental New Treatment (CALY-002) in Healthy Subjects and Subjects With Celiac Disease and Eosinophilic Esophagitis	Phase 1
Completed	`NCT05810441` - Intestinal Transglutaminase Antibodies in Celiac Disease Diagnosis
Recruiting	`NCT05555446` - Bovine Colostrum to Prevent Absorption of Gluten	Early Phase 1
Completed	`NCT02754609` - Hookworm Therapy for Coeliac Disease	Phase 1
Terminated	`NCT01902368` - Celiac Disease Screening	N/A
Completed	`NCT02472704` - Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo	N/A
Completed	`NCT02312349` - Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City
Completed	`NCT01172665` - Celiac Disease Database
Completed	`NCT01100099` - HLA-DQ2-gliadin Tetramer for Diagnosis of Celiac Disease	Phase 2/Phase 3
Completed	`NCT00639444` - Risk of Celiac Disease and Age at Gluten Introduction	N/A
Active, not recruiting	`NCT05425446` - Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients	Phase 1
Enrolling by invitation	`NCT02202681` - Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule	N/A
Completed	`NCT00362856` - Safety and Tolerability Study of Larazotide Acetate in Celiac Disease Subjects	Phase 2
Terminated	`NCT03866538` - Budesonide in Patients With Immune Mediated Enteropathies	Phase 4
Recruiting	`NCT05135923` - Glutenfree, Gut Microbiota and Metabolic Regulation	N/A
Completed	`NCT05052164` - Improvement Of Physical And Physiological Parameters In Menopausal Or Post-Menopausal Celiac Women	N/A
Completed	`NCT03775499` - Probiotic BL NCC 2705 and Gluten Sensitivity	N/A
Completed	`NCT03707730` - A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease	Phase 2